In the past 48 hours, the cannabis industry buzzes with anticipation over potential federal rescheduling in the US, sparked by investor Doug Kasss tweet suggesting an imminent announcement, possibly this week. This has reignited talks on Trade to Black podcast on March 9, boosting investor sentiment amid volatile equities, with Tilray Brands, Canopy Growth, and Cronos Group topping trading volumes as watchlist picks.[1][4]

Key partnerships shine internationally: Curaleaf Laboratories teamed with Sanity Group to innovate UK medical cannabis, while Evidena Care launched Switzerlands first integrated medical cannabis comparison platform.[2] Tilray Brands acquired BrewDog Australia to expand beverages in Asia-Pacific.[5]

Regulatory shifts dominate: Oklahoma Governor Kevin Stitt proposed shutting down the states medical marijuana sector, which boasts over 4300 businesses, employs more than 300000 people wait no, over 300 people per major operator like Mango Cannabis, and raked in 670 million in 2025 sales; critics call it a death blow with legal fallout looming.[6] Positively, Texas eyes more medical dispensaries in 2026,[7] Minnesota inked its eighth Tribal-state cannabis compact on March 9,[8] and Farm Bill talks omitted hemp ban delays, eyeing November 2026 rules.[1]

NewLake Capital Partners reported 12.3 million in Q earnings, beating forecasts with steady cash flow despite capital woes, as CEO Anthony Coniglio eyes re-tenanting and uplisting.[1] No major price swings or supply disruptions noted, but hemp fears persist.

Compared to last week, rescheduling hype has surged from recap videos, while Oklahoma threats mark new disruption versus prior stability. Leaders like NewLake adapt via tenant focus; internationally, firms chase Europe and Asia amid US uncertainty. Consumer behavior holds steady, with medical expansion signals.[1][2][6]

(Word count: 298)

For great deals today, check out https://amzn.to/44ci4hQ

This content was created in partnership and with the help of Artificial Intelligence AI